Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1480-1487

  Raderer, Markus ^b   Becherer, Alexander ^b   Kurtaran, Amir ^b   Angelberger, Peter ^b   Li, Shuren ^b   Leimer, Maria ^b   Weinlaender, Georg ^b   Kornek, Gabriela ^b   Kletter, Kurt ^b   Scheithauer, Werner ^b   Virgolini, Irene ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

gastrointestinal adenocarcinomas; imaging; tumor associated glycoprotein 72; vasoactive intestinal peptide

Indexed keywords

INDIUM 111; IODINE 123; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY CYT 103; ONCOSCINT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE I 123; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSCINTIGRAPHY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SINGLE BLIND PROCEDURE; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; PENTETIC ACID; PROSPECTIVE STUDIES; RADIOIMMUNODETECTION; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SINGLE-BLIND METHOD; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 10144235820     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Silverberg E, Boring CE, Squires TS. Cancer statistics, 1990. CA 1990;40:9-26.
2. Pressman D, Korngold D. The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 1953;6:619-625.
3. Goldenberg DM, Deland F, Kim EE, et al. Use of radiolabeled antibodies to carcino-embryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-1390.
4. Goldenberg, DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803-814.
5. Colcher D, Hand HP, Nuti M, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199-3203.
6. Keenan AM, Colcher D, Larson SM, et al. Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3. J Nucl Med 1984;25:1197-1200.
7. Renda A, Salvatore M, Sava M, et al. Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum. Preliminary report with a new monoclonal antibody B72.3. Dis Colon Rectum 1987;30:683-686.
8. Esteban JM, Colcher D, Sugarbaker P, et al. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987;39:50-59.
9. Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surgery 1991;214:118-124.
10. Abdel-Nabi H, Herrera L, Evans N, et al. Indium-111 CYT-103 MoAb imaging in patients with suspected recurrent colorectal cancer [Abstract]. J Nucl Med 1991;32: 1053.
11. Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179-186.
12. Loy TS, Nashelsky MB. Reactivity of B72.3 with adenocarcinomas. An immunohistochemical study of 476 cases. Cancer 1993;72:2495-2498.
13. Roselli M, Hitchcock CL, Molinolo A, et al. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients. Anticancer Res 1995;15:975-984.
14. Virgolini I, Raderer M, Angelberger P, et al. Vasoactive intestinal peptide (VIP) receptor imaging for the localization of intestinal adenocarcinomas and carcinoid tumors. N Engl J Med 1994;331:1116-1121.
15. Schwartz CJ, Kimberg DV, Sheerin HE, et al. Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa. J Clin Invest 1974;54:536-544.
16. Cohn J. Vasoactive intestinal peptide stimulates protein phosphorylation in a colonic epithelial cell line. Am J Physiol 1987;16:420-424.
17. Pincus DW, DiCicco-Bloom EM, Black IB. Vasoactive intestinal polypeptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 1990;343:564-567.
18. Haegerstrand A, Jonzon B, Daalsgard CJ, et al. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:5993-5996.
19. Virgolini I, Yang Q, Li SR, et al. Cross-competition between vasoactive intestinal peptide (VIP) and somatostatin for binding to tumor cell receptors. Cancer Res 1994;54:690-700.
20. Battari A, Martin JM, Luis J, et al. Solubilization of the active vasoactive intestinal peptide receptor from human colonie adenocarcinoma cells. J Biochem Res 1989;263: 17685-17689.
21. Sreedharan SP, Robichon A, Peterson KE, et al. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc Natl Acad Sci USA 1991;888:4986-4990.
22. Svoboda M, Neef de P, Tastenoy M, et al. Molecular characteristics and evidence for internalization of vasoactive intestinal peptide receptors in the tumoral rat pancreatic acinar cell line AR 4-2J. Eur J Biochem 1988;176:707-713.
23. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995;36:1732-1739.
24. 1 binding capacity. Br J Cancer 1990;61:937-941.
25. 2 and D2 receptor. J Biol Chem 1992;267:12700-12708.
26. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660-672.
27. Greiner JW, Guadagni F, Goldstein D, et al. Intraperitoneal administration of interferon gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992;10:735-746.
28. 111In-CYT-103 antibody under treatment with interferon gamma [Abstract]. J Nucl Med 1994;35:85-86.
29. 111In labeling technique in patients with recurrent colon cancer. Nucl Med Commun 1993;14:658-666.
30. Lamki LM, Podoloff DA, Singletary SE, et al. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 1991;32:1326-1332.
31. Serafini AN, Vargas-Cuba R, Bendetto P, et al. Technetium-99m-labeled Fab fragment of anti-CEA monoclonal antibody for the radioimmunodetection of colorectal adenocarcinoma. Antibody Immunoconjugates Radiopharm 1991;4:561-567.
32. Patt YZ, Podoloff DA, Curley S, et al. Technetium-99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult disease in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol 1994;12: 489-495.